Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD2936 + Tegafur-gimeracil-oteracil Potassium |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD2936 | AZD-2936|AZD 2936|Rilvegostomig | PD-L1/PD-1 antibody 121 TIGIT Antibody 19 | AZD2936 is a bispecific antibody that targets T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and PD-1 (PDCD1), which potentially leads to increased T-lymphocyte antitumor activity, tumor cell killing, and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). | |
Tegafur-gimeracil-oteracil Potassium | TS-1|BMS-247616 | Chemotherapy - Antimetabolite 14 | Tegafur-gimeracil-oteracil Potassium (TS-1) is composed of tegafur, gimestat and otastat potassium, of which the ultimate active ingredient is 5-FU (PMID: 12066214, PMID: 32233637). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06109779 | Phase III | AZD2936 + Cisplatin + Gemcitabine AZD2936 + Tegafur-gimeracil-oteracil Potassium AZD2936 + Capecitabine Capecitabine Tegafur-gimeracil-oteracil Potassium Cisplatin + Gemcitabine | A Study of Rilvegostomig Plus Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Bil01) | Recruiting | USA | TUR | POL | NOR | ITA | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUS | 7 |